Viveve Medical (NASDAQ:VIVE) Issues Quarterly Earnings Results

Viveve Medical (NASDAQ:VIVE) announced its quarterly earnings data on Thursday. The company reported ($13.51) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($16.00) by $2.49, Fidelity Earnings reports. Viveve Medical had a negative net margin of 341.01% and a negative return on equity of 2,976.15%.

Shares of NASDAQ VIVE traded down $0.52 during midday trading on Friday, hitting $3.96. The company’s stock had a trading volume of 244,500 shares, compared to its average volume of 221,374. Viveve Medical has a 1-year low of $3.13 and a 1-year high of $250.00. The firm’s fifty day moving average price is $4.73 and its 200-day moving average price is $1.47. The firm has a market cap of $7.18 million, a P/E ratio of -0.02 and a beta of 0.14.

In other news, major shareholder Goldman Sachs Group Inc sold 92,425 shares of Viveve Medical stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $4.81, for a total value of $444,564.25. Insiders own 5.20% of the company’s stock.

Several brokerages have weighed in on VIVE. LADENBURG THALM/SH SH lowered shares of Viveve Medical from a “buy” rating to a “neutral” rating in a report on Wednesday, July 24th. Mizuho lowered shares of Viveve Medical from a “buy” rating to an “underperform” rating and decreased their price objective for the stock from $4.00 to $0.20 in a report on Tuesday, July 23rd. Raymond James lowered shares of Viveve Medical from an “outperform” rating to a “market perform” rating in a report on Tuesday, July 23rd. Maxim Group reissued a “hold” rating on shares of Viveve Medical in a report on Friday, August 9th. Finally, ValuEngine raised shares of Viveve Medical from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $2.24.

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable components.

Read More: What is a dead cat bounce?

Earnings History for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.